# A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07354711/  
OnCo record `nct07354711` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 3H-10000 in gastric & gastro-oesophageal junction cancer, run by 3H Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07354711 by 3H Pharmaceuticals Co., Ltd., with 170 participants planned, started 2026-01-04 and due to reach its primary completion in 2028-01. Interventions recorded: 3H-10000.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07354711
- Phase: 1/2
- Setting: A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors
- Sponsor: 3H Pharmaceuticals Co., Ltd.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT07354711: https://clinicaltrials.gov/study/NCT07354711

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)

---
JSON: https://onco.cc/api/v1/entities/nct07354711.json